

This PATENT VALUE report was generated by [Pantros IP](#) subject to these [Notes & Terms](#) .

PF/value Report Number **2010127-7479538**

charlesclarke

Patent Number: **US 7479538**

Patent Title: **Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV**

PATENT VALUE REPORT

This **Patent Value Report** separately analyzes the three important factors that IP professionals traditionally use to assess the legal and economic value of an issued US patent. This report is comprised of three primary valuation factors: legal indices, patent value and protected market value.

Although a separate Patent Factor score is provided, all three legal and economic factors are interrelated.

1. Patent Legal Factors
2. Economic Patent Value (as a computed share of the Protected Market)
3. Economic value of the market protected by the patent (as a computed share of the US Gross Domestic Product)

The Patent Value Report Terms (PDF) help interpret the data presented in this report, and are considered an integral part of this Patent Value Report.

Additional information related to patent economic value as presented in this report is available in Pantros IP's [Knowledgebase](#) .

PATENT VALUE PROJECTED MARKET SIZE

Estimated Size of Patent Protected Market: **\$10,493,259.32**

PATENT VALUE PROJECTED PATENT VALUATION

Predicted Patent Value: **\$5,203,874.67**

PATENT VALUE LEGAL SUMMARY

Remaining Life of Patent: **15 Years 6 Months**

charlesclarke ; PF/i Report Number 2010127-7479538

PATENT BIBLIOGRAPHIC DATA

Patent Number: US 7479538

Document Kind: B2

Patent Title:

Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV

Named Inventors:

ZHABILOV HARRY H

Applicants (Assignees):

ZHABILOV TRUST

Agents:

Cislo & Thomas, LLP

Filing Date:

7/11/2005

Issue/Pub Date:

1/20/2009

Patent Termination:

Expires: 7/11/2025

Patent Enforceability Status:

Enforceable

US Classifications / Sub Classes:

530 / 327

530 / 300

435 / 183

435 / 174

435 / 005

435 / 0071

IPC Classifications / Sub Classes:

A61K / 038/04

A61K / 038/10

A61K / 038/17

C07K / 007/00

C07K / 007/04

C07K / 007/08

G01N / 033/53

Abstract:

An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Patent Family Information:

US2006104992A1	07/11/2005	Enforceable	US2009285776A1	06/18/2009	Enforceable
			US7479538B2	07/11/2005	Enforceable

